Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the...

Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference

BALTIMORE, April 27 /PRNewswire/ -- Global progress toward a malaria vaccine is among the key topics to be presented at the 12th Annual Conference on Vaccine Research (ACVR), sponsored by the National Foundation for Infectious Diseases (NFID) April 27-29, 2009 in Baltimore. The ACVR is the world's...

Infant Blood May Provide Insights into Diseases Present at Birth

GRAND RAPIDS, Mich., Dec. 15 /PRNewswire/ -- Van Andel Institute (VAI) researchers are the first to apply a new technology to measure on a large scale the presence of genes in blood spots - the blood drawn from newborn infants to screen for health-threatening conditions. Using a random sample of ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a l...

Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists

MANHATTAN, Kan., Aug. 21 /PRNewswire-USNewswire/ -- Dangerous disease often spreads faster than it takes to diagnose it in the lab. To remedy that, researchers at Kansas State University have developed a test to bring that time from days down to hours. Sanjeev Narayanan, assistant professor,...

Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS

NEW BRUNSWICK, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Underscoring its worldwide commitment to children with HIV/AIDS, Bristol-Myers Squibb Company (NYSE: BMY ) today joined Robert Wood Johnson University Hospital in opening a new clinical center at The Bristol-Myers Squibb Children's Hospit...

Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities

Coalition of Patient and Consumer Groups calls for Legislative Action to Ensure Access to 'Off-Label' Drug Treatments WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Twenty-six patient, family caregiver and health professional organizations are calling upon Congress to pass legisla...

Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting

BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced today data from two studies of the company's ELAD(R) (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which was held November...

Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting

KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, a current standard of care in the trea...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

LOS ANGELES, Aug. 7 /PRNewswire-USNewswire/ -- A new drug delivery system that uses a tiny silicone cup filled with any drug and sealed to the outer surface (episclera) of the eyeball may offer a more effective method for the sustained delivery of medicines for retinal and vitreous disea...

Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases

ROCHESTER, Minn., June 29 /PRNewswire-USNewswire/ -- Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the worl...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases

BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp . After completing initial research, the Company is pursuing clinical trials an...

New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases

Bill would remove financial penalties for participating in research studies BETHESDA, Md., June 15 /PRNewswire-USNewswire/ -- New legislation introduced today would allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for government health...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of s...

Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases

TAMPA, Fla., May 5 /PRNewswire-USNewswire/ -- The Tampa Lions Eye Institute for Transplant and Research, Inc. (LEITR) today announced plans to open a new 12,000-square-foot facility in Tampa, Florida. This state-of-the-art facility will offer high-volume, high-quality human ocular tissue for resea...

Study Shows How Defective DNA Repair Triggers Two Neurological Diseases

St. Jude scientists' findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases MEMPHIS, Tenn., Jan. 14 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's...

42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases

LANSDOWNE, Va., Nov. 18 /PRNewswire-USNewswire/ -- Forty-two leading U. S. scientists and specialists gathered at a November national forum to consider cutting-edge innovations that may defend America's public health and national economy from outbreaks of dangerous zoonotic diseases, the FAZD Cent...

ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases

HALIFAX, Oct. 1 /PRNewswire/ - ImmunoVaccine Technologies' (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy achieved in therapeutic cancer and several infectious disease vaccine models. The results of this research will b...

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases

EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that it had filed a patent application for the use of compounds the company is developing for treatment of brain tumors as potential treatments for neurodegenera...

Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases

Partners Expect Program to Advance to the Clinic Within a Year; Studies Generate Milestone Payment to Micromet BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc. (Nasdaq: MITI ) and Nycomed today announced the initiation of formal preclinical safety...

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/ -- Foamix Ltd, a global leader in the development of dermatological foam medications and Galderma, a worldwide specialty pharmaceutical company focused on dermatology, today announced that they have signed an agreement to d...

Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases

SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR) modulated d...

deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases

REYKJAVIK, Iceland, March 16 /PRNewswire-FirstCall/ -- In a paper published online today in the journal Nature, a team of deCODE scientists detail a major mechanism through which genetic factors contribute to major public health problems. In its work on the inherited components of dozens of co...

St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases

The discovery of a new cytokine called IL-35 could allow clinicians to treat diseases by turning up or down the immune response MEMPHIS, Tenn., Nov. 21 /PRNewswire-USNewswire/ -- Investigators at St. Jude Children's Research Hospital have discovered a new signaling molecule that prevents i...

Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases

Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA ) released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a trea...

Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- A new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) finds that America's pharmaceutical research companies are now testing 338 new medicines to help treat infectious diseases, including 11 medicines and f...

Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases

BRISBANE, Australia, Nov. 5 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced additional data from the Phase 2 liver cancer study of PI-88 completed earlier this year. This data was presented at the 58th Annual Meeting of the American Association...

SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases

SAN DIEGO and MCLEAN, Va., Nov. 1 /PRNewswire-FirstCall/ -- Science Applications International Corporation (NYSE: SAI ) today announced that it was awarded a contract extension by the National Institute of Allergy and Infectious Diseases' (NIAID) Division of Microbiology and Infectious Diseas...

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases

WATERTOWN, Mass., Oct. 17 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimer's, Schizophrenia and Huntington's diseases. EnVivo Phar...

Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases

-Acquisition of Pacific Pharma Technologies Brings Proprietary Artificial Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to Upstream- -Initial Compounds Demonstrate Promising In Vitro Activity Against Devastating Parasitic Diseases Affect...

Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases

PALO ALTO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Mark A. Tarnopolsky, MD, PhD, FRCPC, professor at McMas...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- Quigley Pharma, www.QuigleyPharma.com , a wholly owned subsidiary of The Quigley Corporation announced today that it has completed a follow-up study to evaluate the impact of QR-443 on...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that activation of SIRT1, a member of the sirtuin family of enzymes, was...

Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases

Additional data to be published in an upcoming issue of Anti-Cancer Drugs VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox's PRX 302. The Journal of the National Cancer Institute ("JNCI") has published th...

Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases

BETHESDA, Md., April 10, 2007--In a study appearing in the March 22 New England Journal of Medicine, scientists supported by the National Institutes of Healths National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have discovered a connection between a specific gene and the...

MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases

- Preclinical Data Support Rationale for Targeting Pro-Inflammatory Protein - GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced the publication of preclinical study data demonstrating a role for high mobility group box protein-1 (HMGB1), a nuclear DNA-bind...

Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases

Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Franchise SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- Celgene Corporation announced its plans to advance the development of leading oral anti-inflammatory candidates across a broad range of inflammatory disea...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

... 2009. About Novavax Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant...